Novartis’ IL-1β inhibitor Ilaris (canakinumab) came up short in a Phase III Covid-19 study, the company reported, following an interim analysis of data.
Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.
